vTv Therapeutics (VTVT) Stock Price Down 11%
vTv Therapeutics Inc (NASDAQ:VTVT) shares were down 11% during mid-day trading on Monday . The company traded as low as $2.80 and last traded at $2.92. Approximately 1,479,448 shares changed hands during trading, an increase of 1% from the average daily volume of 1,465,182 shares. The stock had previously closed at $3.28.
Separately, Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $13.11.
The company has a current ratio of 0.19, a quick ratio of 0.19 and a debt-to-equity ratio of -0.15. The company has a market capitalization of $26.59 million, a PE ratio of -1.75 and a beta of 1.62.
In related news, major shareholder Ronald O. Perelman bought 570,777 shares of the stock in a transaction on Friday, August 10th. The shares were bought at an average cost of $4.38 per share, for a total transaction of $2,500,003.26. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ronald O. Perelman bought 1,879,699 shares of the stock in a transaction on Thursday, September 6th. The shares were bought at an average price of $1.33 per share, for a total transaction of $2,499,999.67. The disclosure for this purchase can be found here. Insiders have acquired 4,335,175 shares of company stock worth $7,505,003 over the last 90 days. 2.00% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in vTv Therapeutics stock. Millennium Management LLC boosted its stake in shares of vTv Therapeutics Inc (NASDAQ:VTVT) by 51.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 95,031 shares of the biotechnology company’s stock after buying an additional 32,362 shares during the quarter. Millennium Management LLC owned 0.29% of vTv Therapeutics worth $387,000 as of its most recent filing with the Securities and Exchange Commission. 2.34% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.